{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:31:09Z","timestamp":1769607069849,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1124\/jpet.119.258046","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T19:25:14Z","timestamp":1564773914000},"page":"208-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Inhibition of Interleukin-23\u2013Mediated Inflammation with a Novel Small Molecule Inverse Agonist of ROR\u03b3t"],"prefix":"10.1016","volume":"371","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3389-3493","authenticated-orcid":false,"given":"Stephen B.","family":"Gauld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastien","family":"Jacquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Gauvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4303-4668","authenticated-orcid":false,"given":"Yibing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Goess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Leys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Edelmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Wetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Salte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven P.","family":"McGaraughty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.","family":"Argiriadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prisca","family":"Honore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Luccarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didier","family":"Bressac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Desino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Breinlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Cusack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Potin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Kort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe J","family":"Masson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.258046_bib1","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.bmcl.2019.05.015","article-title":"Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active ROR\u03b3 inverse agonists","volume":"29","author":"Amaudrut","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.119.258046_bib2","unstructured":"Argiriadi M Breinlinger E Cusack K Hobson A Potin D Barth M Amaudrut J Poupardin O Mounier L Kort M (2018) inventors, AbbVie Inc., assignee. Nuclear recptor modulators. U.S. patent 10,106,501 B2, 2018 Oct 23"},{"key":"10.1124\/jpet.119.258046_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/imm.12570","article-title":"Small molecule mediated inhibition of ROR\u03b3-dependent gene expression and autoimmune disease pathology in vivo","volume":"147","author":"Banerjee","year":"2016","journal-title":"Immunology"},{"key":"10.1124\/jpet.119.258046_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrd4518","article-title":"Targeting the IL-17\u2013TH17 pathway","volume":"14","author":"Bartlett","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.119.258046_bib5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/art.40070","article-title":"Secukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator- and placebo-controlled study","volume":"69","author":"Blanco","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1124\/jpet.119.258046_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/13543776.2017.1236918","article-title":"ROR\u03b3 antagonists and inverse agonists: a patent review","volume":"27","author":"Bronner","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"10.1124\/jpet.119.258046_bib7","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.1021\/acs.jmedchem.8b00529","article-title":"Optimizing a weakly binding fragment into a potent ROR\u03b3t inverse agonist with efficacy in an in vivo inflammation model","volume":"61","author":"Carcache","year":"2018","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.258046_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1677\/jme.0.0230255","article-title":"Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription","volume":"23","author":"Collingwood","year":"1999","journal-title":"J Mol Endocrinol"},{"key":"10.1124\/jpet.119.258046_bib9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/ecco-jcc\/jjx079","article-title":"Positioning ustekinumab in Crohn\u2019s disease: from clinical evidence to clinical practice","volume":"11","author":"Danese","year":"2017","journal-title":"J Crohn\u2019s Colitis"},{"key":"10.1124\/jpet.119.258046_bib10","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nature10228","article-title":"Control of TH17 cells occurs in the small intestine","volume":"475","author":"Esplugues","year":"2011","journal-title":"Nature"},{"key":"10.1124\/jpet.119.258046_bib11","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1021\/jm401901d","article-title":"Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-\u03b3 (ROR\u03b3 or RORc)","volume":"57","author":"Fauber","year":"2014","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.258046_bib12","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1021\/acs.jmedchem.5b00597","volume":"58","author":"Fauber","year":"2015","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.258046_bib13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jdermsci.2018.08.001","article-title":"Mechanistic and pharmacological assessment of murine IL-23 mediated psoriasiform dermatitis; implications for drug discovery","volume":"92","author":"Gauld","year":"2018","journal-title":"J Dermatol Sci"},{"key":"10.1124\/jpet.119.258046_bib14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543776.2016.1153066","article-title":"Retinoid-related orphan receptor gamma t (ROR\u03b3t) inhibitors from Vitae Pharmaceuticals (WO2015116904) and structure proposal for their phase I candidate VTP-43742","volume":"26","author":"Gege","year":"2016","journal-title":"Expert Opin Ther Pat"},{"key":"10.1124\/jpet.119.258046_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2017.1262350","article-title":"ROR\u03b3t inhibitors as potential back-ups for the phase II candidate VTP-43742 from Vitae Pharmaceuticals: patent evaluation of WO2016061160 and US20160122345","volume":"27","author":"Gege","year":"2017","journal-title":"Expert Opin Ther Pat"},{"key":"10.1124\/jpet.119.258046_bib16","doi-asserted-by":"crossref","first-page":"e0188391","DOI":"10.1371\/journal.pone.0188391","article-title":"Pharmacological inhibition of ROR\u03b3t suppresses the Th17 pathway and alleviates arthritis in vivo","volume":"12","author":"Guendisch","year":"2017","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.258046_bib17","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1016\/j.celrep.2016.11.073","article-title":"Inhibition of ROR\u03b3T skews TCR\u03b1 gene rearrangement and limits T cell repertoire diversity","volume":"17","author":"Guo","year":"2016","journal-title":"Cell Rep"},{"key":"10.1124\/jpet.119.258046_bib18","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1002\/cmdc.201600500","article-title":"Synthesis and biological evaluation of new triazolo- and imidazolopyridine ROR\u03b3t inverse agonists","volume":"11","author":"Hintermann","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1124\/jpet.119.258046_bib19","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","article-title":"The orphan nuclear receptor ROR\u03b3t directs the differentiation program of proinflammatory IL-17+ T helper cells","volume":"126","author":"Ivanov","year":"2006","journal-title":"Cell"},{"key":"10.1124\/jpet.119.258046_bib20","doi-asserted-by":"crossref","first-page":"e003","DOI":"10.1621\/nrs.07003","article-title":"Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism","volume":"7","author":"Jetten","year":"2009","journal-title":"Nucl Recept Signal"},{"key":"10.1124\/jpet.119.258046_bib21","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/472421a","article-title":"Immunology: a helping hand against autoimmunity","volume":"472","author":"Jetten","year":"2011","journal-title":"Nature"},{"key":"10.1124\/jpet.119.258046_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cotox.2018.01.005","article-title":"Retinoic acid-related orphan receptor \u03b3 (ROR\u03b3): connecting sterol metabolism to regulation of the immune system and autoimmune disease","volume":"8","author":"Jetten","year":"2018","journal-title":"Curr Opin Toxicol"},{"key":"10.1124\/jpet.119.258046_bib23","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cmdc.201700278","article-title":"Structural states of ROR\u03b3t: X-ray elucidation of molecular mechanisms and binding interactions for natural and synthetic compounds","volume":"12","author":"Kallen","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1124\/jpet.119.258046_bib24","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.bbrc.2004.01.131","article-title":"Selective LXXLL peptides antagonize transcriptional activation by the retinoid-related orphan receptor ROR\u03b3","volume":"315","author":"Kurebayashi","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/jpet.119.258046_bib25","doi-asserted-by":"crossref","first-page":"11618","DOI":"10.1074\/jbc.M117.789024","article-title":"Structural studies unravel the active conformation of apo ROR\u03b3t nuclear receptor and a common inverse agonism of two diverse classes of ROR\u03b3t inhibitors","volume":"292","author":"Li","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.119.258046_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0378-1119(96)00504-5","article-title":"Cloning of a cDNA encoding the murine orphan receptor RZR\/ROR\u03b3 and characterization of its response element","volume":"181","author":"Medvedev","year":"1996","journal-title":"Gene"},{"key":"10.1124\/jpet.119.258046_bib27","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1084\/jem.20130376","article-title":"BET bromodomain inhibition suppresses TH17-mediated pathology","volume":"210","author":"Mele","year":"2013","journal-title":"J Exp Med"},{"key":"10.1124\/jpet.119.258046_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/gtc.12494","article-title":"Ternary complex of human ROR\u03b3 ligand-binding domain, inverse agonist and SMRT peptide shows a unique mechanism of corepressor recruitment","volume":"22","author":"Noguchi","year":"2017","journal-title":"Genes Cells"},{"key":"10.1124\/jpet.119.258046_bib29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/BOR.0000000000000301","article-title":"Targeting the interleukin-23\/17 axis in axial spondyloarthritis","volume":"28","author":"Paine","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1124\/jpet.119.258046_bib30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jim.2017.11.001","article-title":"Simple and robust two-step ex vivo whole blood stimulation assay suitable for investigating IL-17 pathway in a clinical laboratory setting","volume":"454","author":"Russell","year":"2018","journal-title":"J Immunol Methods"},{"key":"10.1124\/jpet.119.258046_bib31","doi-asserted-by":"crossref","first-page":"8833","DOI":"10.1038\/ncomms9833","article-title":"Identification of an allosteric binding site for ROR\u03b3t inhibition","volume":"6","author":"Scheepstra","year":"2015","journal-title":"Nat Commun"},{"key":"10.1124\/jpet.119.258046_bib32","doi-asserted-by":"crossref","first-page":"10415","DOI":"10.1021\/acs.jmedchem.8b00392","article-title":"Discovery of 3-cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide: a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C2 inverse agonist","volume":"61","author":"Schnute","year":"2018","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.119.258046_bib33","doi-asserted-by":"crossref","first-page":"4503","DOI":"10.4049\/jimmunol.172.7.4503","article-title":"Immunization with glucose-6-phosphate isomerase induces T cell-dependent peripheral polyarthritis in genetically unaltered mice","volume":"172","author":"Schubert","year":"2004","journal-title":"J Immunol"},{"issue":"Suppl 2","key":"10.1124\/jpet.119.258046_bib34","doi-asserted-by":"crossref","first-page":"ii38","DOI":"10.1093\/rheumatology\/kew349","article-title":"New treatment targets for axial spondyloarthritis","volume":"55","author":"Sieper","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1124\/jpet.119.258046_bib35","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.4049\/jimmunol.1302190","article-title":"Pharmacologic inhibition of ROR\u03b3t regulates Th17 signature gene expression and suppresses cutaneous inflammation in vivo","volume":"192","author":"Skepner","year":"2014","journal-title":"J Immunol"},{"key":"10.1124\/jpet.119.258046_bib36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/imm.12444","article-title":"In vivo regulation of gene expression and T helper type 17 differentiation by ROR\u03b3t inverse agonists","volume":"145","author":"Skepner","year":"2015","journal-title":"Immunology"},{"key":"10.1124\/jpet.119.258046_bib37","doi-asserted-by":"crossref","first-page":"e0147979","DOI":"10.1371\/journal.pone.0147979","article-title":"Development of a topical treatment for psoriasis targeting ROR\u03b3: from bench to skin","volume":"11","author":"Smith","year":"2016","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.258046_bib38","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1124\/jpet.119.258046_bib39","doi-asserted-by":"crossref","first-page":"e84634","DOI":"10.1371\/journal.pone.0084634","article-title":"Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation","volume":"8","author":"Su\u00e1rez-Fari\u00f1as","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.258046_bib40","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1126\/science.288.5475.2369","article-title":"Requirement for ROR\u03b3 in thymocyte survival and lymphoid organ development","volume":"288","author":"Sun","year":"2000","journal-title":"Science"},{"key":"10.1124\/jpet.119.258046_bib41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jdermsci.2016.10.001","article-title":"Oral administration of a novel ROR\u03b3t antagonist attenuates psoriasis-like skin lesion of two independent mouse models through neutralization of IL-17","volume":"85","author":"Takaishi","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.1124\/jpet.119.258046_bib42","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.celrep.2018.04.088","article-title":"Regulation of pathogenic T helper 17 cell differentiation by steroid receptor coactivator-3","volume":"23","author":"Tanaka","year":"2018","journal-title":"Cell Rep"},{"key":"10.1124\/jpet.119.258046_bib43","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1021\/acsmedchemlett.7b00476","article-title":"From ROR\u03b3t agonist to two types of ROR\u03b3t inverse agonists","volume":"9","author":"Wang","year":"2018","journal-title":"ACS Med Chem Lett"},{"key":"10.1124\/jpet.119.258046_bib44","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.bmc.2013.12.021","article-title":"Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent ROR\u03b3t inhibitors","volume":"22","author":"Wang","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/jpet.119.258046_bib45","doi-asserted-by":"crossref","first-page":"27138","DOI":"10.1074\/jbc.M302260200","article-title":"X-ray crystal structure of the liver X receptor \u03b2 ligand binding domain: regulation by a histidine-tryptophan switch","volume":"278","author":"Williams","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.119.258046_bib46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.immuni.2014.04.004","article-title":"Small-molecule ROR\u03b3t antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms","volume":"40","author":"Xiao","year":"2014","journal-title":"Immunity"},{"key":"10.1124\/jpet.119.258046_bib47","doi-asserted-by":"crossref","first-page":"37977","DOI":"10.1038\/srep37977","article-title":"Pharmacologic modulation of ROR\u03b3t translates to efficacy in preclinical and translational models of psoriasis and inflammatory arthritis","volume":"6","author":"Xue","year":"2016","journal-title":"Sci Rep"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524268634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524268634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.258046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T20:07:02Z","timestamp":1739995622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524268634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0022356524268634"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.258046","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of Interleukin-23\u2013Mediated Inflammation with a Novel Small Molecule Inverse Agonist of ROR\u03b3t","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.258046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}